Par Total Current Liabilities vs Property Plant And Equipment Net Analysis

PAR Stock   294.05  12.65  4.50%   
Par Drugs financial indicator trend analysis is much more than just breaking down Par Drugs And prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Par Drugs And is a good investment. Please check the relationship between Par Drugs Total Current Liabilities and its Property Plant And Equipment Net accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Current Liabilities vs Property Plant And Equipment Net

Total Current Liabilities vs Property Plant And Equipment Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Par Drugs And Total Current Liabilities account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have strong relationship.
The correlation between Par Drugs' Total Current Liabilities and Property Plant And Equipment Net is 0.79. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of Par Drugs And, assuming nothing else is changed. The correlation between historical values of Par Drugs' Total Current Liabilities and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Par Drugs And are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Total Current Liabilities i.e., Par Drugs' Total Current Liabilities and Property Plant And Equipment Net go up and down completely randomly.

Correlation Coefficient

0.79
Relationship DirectionPositive 
Relationship StrengthSignificant

Total Current Liabilities

Total Current Liabilities is an item on Par Drugs balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Par Drugs And are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.
Most indicators from Par Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
As of November 23, 2024, Selling General Administrative is expected to decline to about 11.4 M. In addition to that, Tax Provision is expected to decline to about 29.1 M
 2021 2022 2023 2024 (projected)
Total Revenue742.0M951.0M956.4M669.2M
Depreciation And Amortization32.8M32.3M34.4M33.2M

Par Drugs fundamental ratios Correlations

-0.650.72-0.530.95-0.31-0.880.890.320.9-0.32-0.560.440.90.730.49-0.8-0.23-0.170.52-0.710.98-0.740.93-0.260.82
-0.65-0.410.94-0.850.760.87-0.7-0.22-0.680.760.230.02-0.68-0.81-0.590.930.740.01-0.950.98-0.780.96-0.8-0.18-0.88
0.72-0.41-0.230.67-0.22-0.570.590.660.53-0.23-0.350.450.530.810.3-0.590.15-0.190.23-0.470.72-0.510.74-0.380.42
-0.530.94-0.23-0.740.790.83-0.7-0.05-0.650.790.270.2-0.65-0.7-0.660.890.78-0.04-0.920.96-0.630.93-0.69-0.07-0.87
0.95-0.850.67-0.74-0.49-0.940.890.290.87-0.5-0.470.280.870.830.6-0.92-0.43-0.120.73-0.890.98-0.890.97-0.140.92
-0.310.76-0.220.79-0.490.71-0.58-0.32-0.581.00.190.15-0.58-0.63-0.380.760.78-0.1-0.770.75-0.430.79-0.44-0.22-0.62
-0.880.87-0.570.83-0.940.71-0.96-0.31-0.950.710.53-0.18-0.95-0.81-0.60.970.580.11-0.780.92-0.910.95-0.90.12-0.95
0.89-0.70.59-0.70.89-0.58-0.960.290.98-0.59-0.610.20.980.730.61-0.89-0.42-0.140.61-0.80.87-0.840.86-0.330.89
0.32-0.220.66-0.050.29-0.32-0.310.290.25-0.32-0.030.240.250.660.18-0.350.0-0.230.16-0.230.35-0.330.42-0.290.14
0.9-0.680.53-0.650.87-0.58-0.950.980.25-0.59-0.640.291.00.660.48-0.85-0.45-0.140.6-0.760.88-0.80.81-0.190.87
-0.320.76-0.230.79-0.51.00.71-0.59-0.32-0.590.20.14-0.59-0.63-0.380.770.78-0.1-0.770.76-0.440.79-0.45-0.21-0.63
-0.560.23-0.350.27-0.470.190.53-0.61-0.03-0.640.2-0.69-0.64-0.290.090.44-0.090.470.00.34-0.480.36-0.490.31-0.59
0.440.020.450.20.280.15-0.180.20.240.290.14-0.690.290.17-0.51-0.10.38-0.42-0.260.010.39-0.020.310.00.2
0.9-0.680.53-0.650.87-0.58-0.950.980.251.0-0.59-0.640.290.660.48-0.85-0.45-0.140.6-0.760.88-0.80.81-0.190.87
0.73-0.810.81-0.70.83-0.63-0.810.730.660.66-0.63-0.290.170.660.58-0.88-0.38-0.110.7-0.840.81-0.880.88-0.210.73
0.49-0.590.3-0.660.6-0.38-0.60.610.180.48-0.380.09-0.510.480.58-0.64-0.430.180.65-0.670.52-0.660.63-0.450.57
-0.80.93-0.590.89-0.920.760.97-0.89-0.35-0.850.770.44-0.1-0.85-0.88-0.640.60.12-0.840.97-0.870.98-0.90.1-0.94
-0.230.740.150.78-0.430.780.58-0.420.0-0.450.78-0.090.38-0.45-0.38-0.430.6-0.27-0.890.67-0.350.69-0.3-0.46-0.57
-0.170.01-0.19-0.04-0.12-0.10.11-0.14-0.23-0.14-0.10.47-0.42-0.14-0.110.180.12-0.270.170.05-0.110.06-0.180.2-0.21
0.52-0.950.23-0.920.73-0.77-0.780.610.160.6-0.770.0-0.260.60.70.65-0.84-0.890.17-0.90.65-0.90.650.260.77
-0.710.98-0.470.96-0.890.750.92-0.8-0.23-0.760.760.340.01-0.76-0.84-0.670.970.670.05-0.9-0.810.99-0.860.0-0.93
0.98-0.780.72-0.630.98-0.43-0.910.870.350.88-0.44-0.480.390.880.810.52-0.87-0.35-0.110.65-0.81-0.830.96-0.140.86
-0.740.96-0.510.93-0.890.790.95-0.84-0.33-0.80.790.36-0.02-0.8-0.88-0.660.980.690.06-0.90.99-0.83-0.860.03-0.92
0.93-0.80.74-0.690.97-0.44-0.90.860.420.81-0.45-0.490.310.810.880.63-0.9-0.3-0.180.65-0.860.96-0.86-0.310.88
-0.26-0.18-0.38-0.07-0.14-0.220.12-0.33-0.29-0.19-0.210.310.0-0.19-0.21-0.450.1-0.460.20.260.0-0.140.03-0.31-0.1
0.82-0.880.42-0.870.92-0.62-0.950.890.140.87-0.63-0.590.20.870.730.57-0.94-0.57-0.210.77-0.930.86-0.920.88-0.1
Click cells to compare fundamentals

Par Drugs Account Relationship Matchups

Par Drugs fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets601.2M763.8M786.9M888.7M1.0B763.9M
Short Long Term Debt Total231.3M115.8M60.1M83.2M74.9M139.5M
Other Current Liab2.5M19.7M42.0M59.0M21.0M20.4M
Total Current Liabilities108.4M159.8M148.6M139.9M124.4M123.4M
Total Stockholder Equity406.1M522.1M598.8M712.4M856.3M483.9M
Property Plant And Equipment Net351.4M343.7M343.5M386.9M413.3M305.2M
Net Debt(13.7M)(128.4M)(162.1M)(222.4M)(366.5M)(348.2M)
Retained Earnings175.3M291.3M368.0M481.6M625.5M656.8M
Accounts Payable62.0M67.2M106.6M80.9M53.6M75.1M
Cash73.8M211.6M162.1M222.4M366.5M384.9M
Non Current Assets Total359.0M352.0M351.3M394.3M419.9M311.6M
Non Currrent Assets Other7.1M8.2M7.6M7.3M6.4M6.3M
Other Assets7.1M7.6M7.6M7.3M8.4M5.1M
Cash And Short Term Investments73.8M211.6M162.1M222.4M366.5M384.9M
Net Receivables139.2M126.2M217.4M218.2M138.1M145.9M
Liabilities And Stockholders Equity601.2M763.8M786.9M888.7M1.0B763.9M
Non Current Liabilities Total86.6M81.9M39.6M36.4M35.4M33.6M
Inventory29.2M30.0M47.1M53.8M44.2M34.4M
Other Current Assets(1.0)35.1M9.1M(1K)372K353.4K
Other Stockholder Equity99.7M168.2M168.2M106.7M122.7M92.7M
Total Liab195.0M241.7M188.1M176.3M159.8M203.6M
Total Current Assets242.2M411.9M435.6M494.4M596.2M335.4M
Short Term Debt13.9M39.3M90K623K(51K)(48.5K)
Current Deferred Revenue30.0M46.5M90K623K51K48.5K
Other Liab37.5M40.4M38.0M39.5M45.5M41.5M
Net Tangible Assets290.3M406.1M522.1M598.8M688.6M433.3M
Net Invested Capital466.3M598.5M598.8M712.4M856.3M631.7M
Net Working Capital133.7M252.1M287.1M354.5M471.8M495.4M
Property Plant Equipment363.4M351.4M344.3M343.5M309.2M286.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

Balance Sheet is a snapshot of the financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Par Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Par Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Par currently owns. An asset can also be divided into two categories, current and non-current.